Abstract
To the Editor—In their 1999 case report, Campisi and colleagues1 advised caution in prescribing Fleet® Phospho-soda® (CB Fleet Co., Inc., Lynchburg, VA) for patients taking bisphosphonates. They reported that their subject patient, who had been on a bisphos-phonate, Fosamax®, (Merck Human Health Division, West Point, PA) for several years, suffered hypocalcemic-induced tetany when taking Fleet® Phospho-so-da® before colonoscopy. At least three issues should be noted with this serious adverse event:
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcmie tetany caused by Fleet® Phospho-Soda® preparation in a patient taking alendronate sodium: report of a case. Dis Colon Rectum 1999;42:l499–501.
Ferguson KH, McNeil JJ, Morey AF. Mechanical and antibiotic bowel preparation for urinary diversion surgery. J Urol 2002;l67:2352–6.
Caswell M. Bowel preparations and hyperphosphataemia. Anaesthesia 2002;57:1236.
Francis MD, Webb NC. Hydroxyapatite formation from a hydrated calcium monohydrogen phosphate precursor. Calcif Tissue Res 1971;6:335–42.
Hebert LA, Lemann J Jr., Petersen JR, Lennon EJ. Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1996;45:1886–94.
Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7:513–22.
Ebetino FH, Francis MD, Rogers MJ, Russell RG. Mechanism of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother 1998;9:233–43.
Author information
Authors and Affiliations
About this article
Cite this article
Frincis, M.O., Caswell, M. Patients on bisphosphonates should not be at increased risk for hypocalcemic-induced tetany when given fleet® phosphosoda®. Dis Colon Rectum 46, 1717–1718 (2003). https://doi.org/10.1007/BF02660784
Issue Date:
DOI: https://doi.org/10.1007/BF02660784